What is the appropriate evaluation and management for a patient with systemic lupus erythematosus who presents with chest pain and cough?

Chest Pain and Cough in Lupus: Evaluation and Management

A patient with systemic lupus erythematosus presenting with chest pain and cough requires urgent evaluation for serositis (pleuritis/pericarditis), infection, and life-threatening pulmonary complications including acute lupus pneumonitis and diffuse alveolar hemorrhage.

Immediate Diagnostic Approach

Clinical Assessment Priority

The combination of chest pain and cough in SLE demands a high index of suspicion for multiple serious conditions 1:

Most Common Causes:

• Serositis (pleuritis/pericarditis) - most frequent pulmonary manifestation
• Infection - SLE patients have significantly increased infection risk due to disease and immunosuppression 2
• Acute lupus pneumonitis - rare but life-threatening 3
• Diffuse alveolar hemorrhage (DAH) - occurs in 1.9% of SLE patients with 48% mortality 4

Essential Initial Workup

Laboratory Tests:

• Complete blood count (looking for anemia suggesting DAH, lymphopenia <500 cells/mm³, thrombocytopenia) 1
• Serum creatinine and urinalysis (proteinuria, active sediment)
• Complement levels (C3/C4) and anti-dsDNA antibodies 1
• Inflammatory markers (ESR, CRP)

Imaging:

• Chest radiography - immediate first step 5
• High-resolution CT chest if radiograph abnormal or symptoms persist 5, 6
• Echocardiography if pericarditis suspected

Pulmonary Function Tests:

• Spirometry and DLCO for symptomatic patients 5
• Restrictive pattern with reduced DLCO suggests interstitial involvement 6, 7

Critical Rule-Outs

Infection Must Be Rigorously Excluded First 8:

• SLE patients are at high risk for tuberculosis, pneumococcus, and opportunistic infections 2
• Screen for HIV, HCV, HBV based on risk factors 2
• Consider CMV testing in patients on high-dose immunosuppression 2
• Blood cultures, sputum cultures if productive cough
• No pulmonary process should be attributed to lupus until infection has been excluded 8

Specific Diagnostic Considerations

Serositis (Most Common)

• Pleuritic chest pain, often positional
• May have pleural effusion on imaging
• Monitor with validated activity indices (BILAG, SLEDAI, ECLAM) 1

Acute Lupus Pneumonitis

• Fever, dyspnea, pleuritic chest pain 3
• Bilateral infiltrates on imaging
• Requires exclusion of infection and cardiac causes
• Life-threatening - requires aggressive treatment

Diffuse Alveolar Hemorrhage

• Dyspnea (94%), anemia (97%), new chest infiltrates (99%) 4
• Bronchoscopy identifies DAH in 90% of cases when performed 4
• Hemoptysis may be absent initially
• 48% mortality despite treatment 4

Interstitial Lung Disease

• Rare in SLE (1-15% prevalence) 5
• NSIP most common pattern
• Risk factors: male sex, older age, anti-Sm, anti-U1-RNP antibodies 5
• Chronic dry cough, reduced DLCO 6

Shrinking Lung Syndrome

• Progressive dyspnea, pleuritic chest pain, dry cough 7
• Elevated diaphragmatic domes on imaging
• Restrictive pattern with reduced DLCO
• Diaphragmatic ultrasound shows reduced excursion 7

Treatment Algorithm

Mild Serositis Without Major Organ Involvement

• NSAIDs for limited periods in low-risk patients 1
• Antimalarials (hydroxychloroquine) and/or glucocorticoids 1
• If non-responsive or unable to reduce steroids: add azathioprine, mycophenolate mofetil, or methotrexate 1

Severe Pleuritis/Pericarditis

• High-dose glucocorticoids 8, 9
• Pulse methylprednisolone for pericardial tamponade 9
• Consider immunosuppressives (cyclophosphamide, rituximab) for refractory cases 9

Acute Lupus Pneumonitis

• High-dose systemic corticosteroids immediately 3, 9
• Cyclophosphamide for severe or steroid-unresponsive cases 8, 9
• Consider rituximab as second-line 9
• Mortality 40-60% despite aggressive therapy 9

Diffuse Alveolar Hemorrhage

• Pulse methylprednisolone (1g IV daily × 3 days) 4, 9
• Cyclophosphamide (0.5-1g/m² IV monthly) 4, 8
• Plasmapheresis for refractory cases 4, 8, 9
• Rituximab as second-line option 4, 9
• Recombinant Factor VII for persistent bleeding 4

Interstitial Lung Disease

• Glucocorticoids plus immunosuppressives (mycophenolate mofetil or cyclophosphamide) 10, 8
• Anti-fibrotic therapy (nintedanib, pirfenidone) has no proven benefit in SLE-ILD 9

Shrinking Lung Syndrome

• Immunosuppressive therapy beyond corticosteroids 7
• Rituximab most commonly used agent 7
• 62.5% show improvement in pulmonary function 7

Critical Pitfalls to Avoid

1. Never attribute symptoms to lupus before excluding infection - infections are a leading cause of death in SLE 1, 8

2. Don't rely on hemoptysis to diagnose DAH - it may be absent initially 4

3. Don't misinterpret pulmonary function tests - preserved FEV1/FVC ratio with reduced DLCO may still represent significant disease 6

4. Don't delay bronchoscopy when DAH is suspected - it's diagnostic in 90% of cases 4

5. Monitor for co-morbidities - atherosclerosis, hypertension, diabetes, osteoporosis are increased in SLE 1

Monitoring During Treatment

• Assess disease activity at each visit using validated indices 1, 2
• Repeat imaging and PFTs based on clinical response 5
• Screen for infections continuously - severe neutropenia (<500/mm³), lymphopenia (<500/mm³), low IgG (<500 mg/dL) increase infection risk 2
• Monitor for treatment toxicity - particularly with cyclophosphamide and high-dose steroids 1